{
  "report_rows": [
    {
      "kpi": "DUPIXENT Global Sales (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~$5,450M vs. cons $5,367M",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Non-GAAP EPS Diluted (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~$10.35 vs. cons $10.10",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "EYLEA HD US Net Sales (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~$535M vs. cons $527M",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY 2026 GAAP Gross Margin (FY 2026)",
      "prediction": "UNCHANGED",
      "answer": "guide 77-78% vs. cons ~77-78%",
      "confidence": "HIGH"
    },
    {
      "kpi": "Sanofi Profit Share Step-Up (Q3 2026 qualitative)",
      "prediction": "BETTER",
      "answer": "guide above consensus H2 EPS modeling",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "DUPIXENT Q3 Trajectory (qualitative)",
      "prediction": "UNCHANGED",
      "answer": "guide continued growth, moderating comps vs. cons ~$5.5B Q3",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": 2.5,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 3.5,
  "day5_path": "FOLLOW-THROUGH",
  "day5_rationale": "FOLLOW-THROUGH \u2014 H2 EPS estimate revisions driven by Sanofi profit share step-up confirmation",
  "day5_confidence": "MEDIUM"
}